Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies
Identifieur interne : 002071 ( Main/Corpus ); précédent : 002070; suivant : 002072Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies
Auteurs : Peggy Reiner ; Damien Galanaud ; Gaëlle Leroux ; Marie Vidailhet ; Julien Haroche ; Du Le Thi Huong ; Camille Francès ; Thomas Papo ; Christian De Gennes ; Lucile Musset ; Bertrand Wechsler ; Zahir Amoura ; Jean-Charles Piette ; Nathalie Costedoat-ChalumeauSource :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
- KwdEn :
Abstract
Objective:: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome. Methods:: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results:: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases. Conclusions:: Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23863
Links to Exploration step
ISTEX:D4F441530FB5E899F88F218D9988BAF91B915591Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title><author><name sortKey="Reiner, Peggy" sort="Reiner, Peggy" uniqKey="Reiner P" first="Peggy" last="Reiner">Peggy Reiner</name><affiliation><mods:affiliation>Service de Neurologie, AP‐HP, Hôpital Lariboisière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Galanaud, Damien" sort="Galanaud, Damien" uniqKey="Galanaud D" first="Damien" last="Galanaud">Damien Galanaud</name><affiliation><mods:affiliation>Service de Neuroradiologie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leroux, Gaelle" sort="Leroux, Gaelle" uniqKey="Leroux G" first="Gaëlle" last="Leroux">Gaëlle Leroux</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><affiliation><mods:affiliation>Fédération des Maladies du Système Nerveux Central, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Haroche, Julien" sort="Haroche, Julien" uniqKey="Haroche J" first="Julien" last="Haroche">Julien Haroche</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Huong, Du Le Thi" sort="Huong, Du Le Thi" uniqKey="Huong D" first="Du Le Thi" last="Huong">Du Le Thi Huong</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Frances, Camille" sort="Frances, Camille" uniqKey="Frances C" first="Camille" last="Francès">Camille Francès</name><affiliation><mods:affiliation>Service de Dermatologie, Hôpital Tenon, AP‐HP, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name><affiliation><mods:affiliation>Service de Médecine Interne, AP‐HP, Hôpital Bichat, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="De Gennes, Christian" sort="De Gennes, Christian" uniqKey="De Gennes C" first="Christian" last="De Gennes">Christian De Gennes</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Musset, Lucile" sort="Musset, Lucile" uniqKey="Musset L" first="Lucile" last="Musset">Lucile Musset</name><affiliation><mods:affiliation>Service d'Immunochimie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Wechsler, Bertrand" sort="Wechsler, Bertrand" uniqKey="Wechsler B" first="Bertrand" last="Wechsler">Bertrand Wechsler</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Amoura, Zahir" sort="Amoura, Zahir" uniqKey="Amoura Z" first="Zahir" last="Amoura">Zahir Amoura</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Piette, Jean Harles" sort="Piette, Jean Harles" uniqKey="Piette J" first="Jean-Charles" last="Piette">Jean-Charles Piette</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Costedoat Halumeau, Nathalie" sort="Costedoat Halumeau, Nathalie" uniqKey="Costedoat Halumeau N" first="Nathalie" last="Costedoat-Chalumeau">Nathalie Costedoat-Chalumeau</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D4F441530FB5E899F88F218D9988BAF91B915591</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23863</idno><idno type="url">https://api.istex.fr/document/D4F441530FB5E899F88F218D9988BAF91B915591/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002071</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title><author><name sortKey="Reiner, Peggy" sort="Reiner, Peggy" uniqKey="Reiner P" first="Peggy" last="Reiner">Peggy Reiner</name><affiliation><mods:affiliation>Service de Neurologie, AP‐HP, Hôpital Lariboisière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Galanaud, Damien" sort="Galanaud, Damien" uniqKey="Galanaud D" first="Damien" last="Galanaud">Damien Galanaud</name><affiliation><mods:affiliation>Service de Neuroradiologie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leroux, Gaelle" sort="Leroux, Gaelle" uniqKey="Leroux G" first="Gaëlle" last="Leroux">Gaëlle Leroux</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><affiliation><mods:affiliation>Fédération des Maladies du Système Nerveux Central, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Haroche, Julien" sort="Haroche, Julien" uniqKey="Haroche J" first="Julien" last="Haroche">Julien Haroche</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Huong, Du Le Thi" sort="Huong, Du Le Thi" uniqKey="Huong D" first="Du Le Thi" last="Huong">Du Le Thi Huong</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Frances, Camille" sort="Frances, Camille" uniqKey="Frances C" first="Camille" last="Francès">Camille Francès</name><affiliation><mods:affiliation>Service de Dermatologie, Hôpital Tenon, AP‐HP, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name><affiliation><mods:affiliation>Service de Médecine Interne, AP‐HP, Hôpital Bichat, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="De Gennes, Christian" sort="De Gennes, Christian" uniqKey="De Gennes C" first="Christian" last="De Gennes">Christian De Gennes</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Musset, Lucile" sort="Musset, Lucile" uniqKey="Musset L" first="Lucile" last="Musset">Lucile Musset</name><affiliation><mods:affiliation>Service d'Immunochimie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Wechsler, Bertrand" sort="Wechsler, Bertrand" uniqKey="Wechsler B" first="Bertrand" last="Wechsler">Bertrand Wechsler</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Amoura, Zahir" sort="Amoura, Zahir" uniqKey="Amoura Z" first="Zahir" last="Amoura">Zahir Amoura</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Piette, Jean Harles" sort="Piette, Jean Harles" uniqKey="Piette J" first="Jean-Charles" last="Piette">Jean-Charles Piette</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Costedoat Halumeau, Nathalie" sort="Costedoat Halumeau, Nathalie" uniqKey="Costedoat Halumeau N" first="Nathalie" last="Costedoat-Chalumeau">Nathalie Costedoat-Chalumeau</name><affiliation><mods:affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2422">2422</biblScope><biblScope unit="page" to="2427">2427</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D4F441530FB5E899F88F218D9988BAF91B915591</idno><idno type="DOI">10.1002/mds.23863</idno><idno type="ArticleID">MDS23863</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antiphospholipid</term><term>chorea</term><term>lupus</term><term>thrombosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective:: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome. Methods:: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results:: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases. Conclusions:: Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Peggy Reiner MD</name><affiliations><json:string>Service de Neurologie, AP‐HP, Hôpital Lariboisière, Paris, France</json:string></affiliations></json:item><json:item><name>Damien Galanaud MD, PhD</name><affiliations><json:string>Service de Neuroradiologie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Gaëlle Leroux MD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Marie Vidailhet MD</name><affiliations><json:string>Fédération des Maladies du Système Nerveux Central, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Julien Haroche MD, PhD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Du Le Thi Huong MD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Camille Francès MD</name><affiliations><json:string>Service de Dermatologie, Hôpital Tenon, AP‐HP, Paris, France</json:string></affiliations></json:item><json:item><name>Thomas Papo MD</name><affiliations><json:string>Service de Médecine Interne, AP‐HP, Hôpital Bichat, Paris, France</json:string></affiliations></json:item><json:item><name>Christian de Gennes MD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Lucile Musset MD, PhD</name><affiliations><json:string>Service d'Immunochimie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Bertrand Wechsler MD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Zahir Amoura MD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Jean‐Charles Piette MD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Nathalie Costedoat‐Chalumeau MD, PhD</name><affiliations><json:string>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>chorea</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antiphospholipid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>lupus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>thrombosis</value></json:item></subject><articleId><json:string>MDS23863</json:string></articleId><language><json:string>eng</json:string></language><abstract>Objective:: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome. Methods:: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results:: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases. Conclusions:: Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.932</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1134</abstractCharCount><pdfWordCount>14214</pdfWordCount><pdfCharCount>97058</pdfCharCount><pdfPageCount>23</pdfPageCount><abstractWordCount>161</abstractWordCount></qualityIndicators><title>Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>2427</last><first>2422</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23863</json:string></doi><id>D4F441530FB5E899F88F218D9988BAF91B915591</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D4F441530FB5E899F88F218D9988BAF91B915591/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D4F441530FB5E899F88F218D9988BAF91B915591/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D4F441530FB5E899F88F218D9988BAF91B915591/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This work received no financial support.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles can be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title><author><persName><forename type="first">Peggy</forename><surname>Reiner</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Service de Neurologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France</p></note><affiliation>Service de Neurologie, AP‐HP, Hôpital Lariboisière, Paris, France</affiliation></author><author><persName><forename type="first">Damien</forename><surname>Galanaud</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Neuroradiologie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Gaëlle</forename><surname>Leroux</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Marie</forename><surname>Vidailhet</surname></persName><roleName type="degree">MD</roleName><affiliation>Fédération des Maladies du Système Nerveux Central, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Julien</forename><surname>Haroche</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Du Le Thi</forename><surname>Huong</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Camille</forename><surname>Francès</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Dermatologie, Hôpital Tenon, AP‐HP, Paris, France</affiliation></author><author><persName><forename type="first">Thomas</forename><surname>Papo</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, AP‐HP, Hôpital Bichat, Paris, France</affiliation></author><author><persName><forename type="first">Christian</forename><surname>de Gennes</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Lucile</forename><surname>Musset</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service d'Immunochimie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Bertrand</forename><surname>Wechsler</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Zahir</forename><surname>Amoura</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Jean‐Charles</forename><surname>Piette</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Nathalie</forename><surname>Costedoat‐Chalumeau</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2422">2422</biblScope><biblScope unit="page" to="2427">2427</biblScope></imprint></monogr><idno type="istex">D4F441530FB5E899F88F218D9988BAF91B915591</idno><idno type="DOI">10.1002/mds.23863</idno><idno type="ArticleID">MDS23863</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Objective:: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome. Methods:: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results:: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases. Conclusions:: Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>chorea</term></item><item><term>antiphospholipid</term></item><item><term>lupus</term></item><item><term>thrombosis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-10-28">Received</change><change when="2011-06-12">Registration</change><change when="2011-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D4F441530FB5E899F88F218D9988BAF91B915591/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v26.13</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2011-11">November 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="200" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23863</doi><idGroup><id type="unit" value="MDS23863"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-10-28"></event><event type="manuscriptRevised" date="2011-05-14"></event><event type="manuscriptAccepted" date="2011-06-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-07-13"></event><event type="publishedOnlineFinalForm" date="2011-11-22"></event><event type="firstOnline" date="2011-07-13"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2422</numbering><numbering type="pageLast">2427</numbering></numberingGroup><correspondenceTo>Service de Neurologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23863.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="26"></count><count type="wordTotal" number="5433"></count></countGroup><titleGroup><title type="main" xml:lang="en">Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies<link href="#fn7"></link><link href="#fn8"></link><link href="#fn9"></link></title><title type="short" xml:lang="en">Long‐Term Outcome of 32 Patients</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Peggy</givenNames><familyName>Reiner</familyName><degrees>MD</degrees></personName><contactDetails><email>peggyreiner@yahoo.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Damien</givenNames><familyName>Galanaud</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Gaëlle</givenNames><familyName>Leroux</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Marie</givenNames><familyName>Vidailhet</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Julien</givenNames><familyName>Haroche</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Du Le Thi</givenNames><familyName>Huong</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Camille</givenNames><familyName>Francès</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Thomas</givenNames><familyName>Papo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Christian</givenNames><familyName>de Gennes</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Lucile</givenNames><familyName>Musset</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Bertrand</givenNames><familyName>Wechsler</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Zahir</givenNames><familyName>Amoura</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jean‐Charles</givenNames><familyName>Piette</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Nathalie</givenNames><familyName>Costedoat‐Chalumeau</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Service de Neurologie, AP‐HP, Hôpital Lariboisière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Service de Neuroradiologie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Fédération des Maladies du Système Nerveux Central, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Service de Dermatologie, Hôpital Tenon, AP‐HP, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="FR" type="organization"><unparsedAffiliation>Service de Médecine Interne, AP‐HP, Hôpital Bichat, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="FR" type="organization"><unparsedAffiliation>Service d'Immunochimie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">chorea</keyword><keyword xml:id="kwd2">antiphospholipid</keyword><keyword xml:id="kwd3">lupus</keyword><keyword xml:id="kwd4">thrombosis</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Objective:</title><p>The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; <i>P</i> = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases.</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn7"><p><b>Funding agencies:</b> This work received no financial support.</p></note><note xml:id="fn8"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn9"><p>Full financial disclosures and author roles can be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Long‐Term Outcome of 32 Patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies</title></titleInfo><name type="personal"><namePart type="given">Peggy</namePart><namePart type="family">Reiner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Neurologie, AP‐HP, Hôpital Lariboisière, Paris, France</affiliation><description>Correspondence: Service de Neurologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Damien</namePart><namePart type="family">Galanaud</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Neuroradiologie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gaëlle</namePart><namePart type="family">Leroux</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marie</namePart><namePart type="family">Vidailhet</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Fédération des Maladies du Système Nerveux Central, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Julien</namePart><namePart type="family">Haroche</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Du Le Thi</namePart><namePart type="family">Huong</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Camille</namePart><namePart type="family">Francès</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Dermatologie, Hôpital Tenon, AP‐HP, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Papo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, AP‐HP, Hôpital Bichat, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christian</namePart><namePart type="family">de Gennes</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lucile</namePart><namePart type="family">Musset</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service d'Immunochimie, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bertrand</namePart><namePart type="family">Wechsler</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Zahir</namePart><namePart type="family">Amoura</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Charles</namePart><namePart type="family">Piette</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nathalie</namePart><namePart type="family">Costedoat‐Chalumeau</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP‐HP, Centre Hospitalier Universitaire Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-11</dateIssued><dateCaptured encoding="w3cdtf">2010-10-28</dateCaptured><dateValid encoding="w3cdtf">2011-06-12</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">26</extent><extent unit="words">5433</extent></physicalDescription><abstract lang="en">Objective:: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome. Methods:: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results:: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases. Conclusions:: Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This work received no financial support.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles can be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>chorea</topic><topic>antiphospholipid</topic><topic>lupus</topic><topic>thrombosis</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>2422</start><end>2427</end><total>6</total></extent></part></relatedItem><identifier type="istex">D4F441530FB5E899F88F218D9988BAF91B915591</identifier><identifier type="DOI">10.1002/mds.23863</identifier><identifier type="ArticleID">MDS23863</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002071 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002071 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D4F441530FB5E899F88F218D9988BAF91B915591
|texte= Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies
}}
| This area was generated with Dilib version V0.6.23. |  |